Physician profile
Christopher S Thompson
NPI 1225135478
$3,426.97
in general payments reported to CMS, 2019-2025
24 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $104 · 2021: $504 · 2022: $720 · 2023: $450 · 2024: $293 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $580.34 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $498.12 | 2019-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $428.21 | 2019-2024 | |
| Abiomed | $415.23 | 2019-2025 | Impella |
| Janssen Pharmaceuticals, INC | $239.31 | 2019-2022 | |
| Edwards Lifesciences Corporation | $213.43 | 2019-2024 | |
| Pfizer INC. | $133.75 | 2019-2022 | |
| Shockwave Medical, INC | $133.30 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $125.66 | 2022 | |
| Boston Scientific Corporation | $120.17 | 2019 | |
| Amarin Pharma, INC. | $72.14 | 2021-2022 | |
| Angiodynamics, INC. | $71.85 | 2023 | Alphavac |
| Merck Sharp & Dohme LLC | $53.27 | 2022-2025 | Verquvo |
| Abbott Laboratories | $52.32 | 2022-2025 | Xience Skypoint |
| Astrazeneca Pharmaceuticals LP | $46.13 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.75 | 2022-2025 | Jardiance |
| Medtronic Vascular, INC. | $39.19 | 2019-2020 | |
| Cardiva Medical, INC. | $30.70 | 2025 | Cardiva Vascade 6/7f Vcs |
| Amgen INC. | $30.64 | 2020-2022 | |
| Biogen, INC. | $26.57 | 2024 | Skyclarys |
| Bardy Diagnostics, INC. | $24.31 | 2022 | |
| Itamar Medical INC | $20.58 | 2024 | Watchpatone |
| Esperion Therapeutics, INC. | $14.71 | 2021 | |
| Gilead Sciences, INC. | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.